Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mistletoe extract, derived from the Viscum album plant, is a botanical product investigated as a complementary therapy for cancer. The National Center for Complementary and Integrative Health (NCCIH) sponsored a Phase I clinical trial evaluating the extract in combination with gemcitabine for patients with advanced solid tumors. [1] Mistletoe extract is believed to exert its effects through multiple mechanisms, including immunomodulation, induction of apoptosis (programmed cell death) in cancer cells, and direct cytotoxicity. [2, 3] Studies suggest it can improve the quality of life and reduce the adverse effects of chemotherapy in patients with various cancers, such as breast, ovarian, and non-small cell lung cancer. [3] Preparations are not standardized across manufacturers and can vary based on the host tree, time of harvest, and extraction process. [9]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on viscum album extract (Helixor Heilmittel GmbH).